TITLE: Psychedelic Policy Briefing: FDA Seeks Ibogaine Trial Input, Compass Prepares COMP360 Launch, and DEA Faces State-Level Questions
EXCERPT: The latest psychedelic policy developments include the FDA’s request for public input on ibogaine clinical trials, Compass Pathways’ plans for COMP360 pricing and reimbursement, and growing frustration among state cannabis regulators over unanswered questions about marijuana rescheduling.
ARTICLE HTML:
In this week’s psychedelic policy briefing, investigative journalist Jack Gorsline, founder of Psychedelic State(s) of America, examines three developments shaping the future of psychedelic medicine and drug policy in the United States. The Food and Drug Administration (FDA) is seeking public feedback on safety measures for federally funded ibogaine clinical trials. Meanwhile, Compass Pathways is discussing pricing and insurance reimbursement for COMP360, its synthetic psilocybin treatment for treatment-resistant depression, as it prepares to complete its new drug application. At the same time, state cannabis regulators say the Drug Enforcement Administration (DEA) has left important questions about marijuana rescheduling unanswered. These developments highlight a broader challenge: even if the FDA approves a psychedelic medicine, DEA scheduling decisions and coordination with state authorities will influence how quickly patients can access it.
Federal Regulatory Update: FDA Seeks Public Input on Ibogaine Trial Design
On October 5, the FDA issued a formal request for information under docket FDA-2026-N-10429. The agency is inviting researchers, clinicians, potential clinical trial sponsors, patients, and members of the public to comment on the safety, dosing, and oversight of early-stage ibogaine trials.
The proposed trials would receive federal support from the National Institute on Drug Abuse and the Advanced Research Projects Agency for Health (ARPA-H). They are expected to enroll adults with post-traumatic stress disorder (PTSD) and opioid use disorder (OUD), consistent with Executive Order 14401, signed in April. According to the FDA notice, the only related study the agency has permitted to proceed is an early-phase trial of noribogaine, a derivative of ibogaine, for alcohol use disorder.
Safety is a central concern because ibogaine can cause serious cardiac complications. One particular risk is QTc interval prolongation, a change in the heart’s electrical activity associated with potentially fatal ventricular arrhythmias and death. In response, the FDA has outlined preliminary safeguards for the proposed research and is asking the public whether those measures are appropriate.
Under the suggested framework, participants would receive treatment in small groups, with each group receiving a single dose before researchers consider increasing the dose for the next group. The initial dose would not exceed 10 milligrams per kilogram of body weight. The FDA is specifically asking whether this proposed maximum is suitable for early-stage trials.
Administration would take place in an inpatient facility equipped for continuous cardiac rhythm monitoring, advanced life support, and emergency pacing. Monitoring could continue for as long as 36 hours, and participants would be required to remain hospitalized for at least that period. At least two staff members would supervise each participant during the acute effects of treatment, including at least one licensed mental health professional.
The proposed precautions also address electrolyte levels. Low potassium, calcium, or magnesium would need to be corrected before a participant receives ibogaine. Trial sponsors could also investigate whether giving magnesium intravenously before treatment helps reduce the drug’s cardiac risks.
The FDA emphasized that these proposed guidelines are not legally binding requirements. They also do not determine in advance whether the agency will approve any particular investigational new drug application.
For participants with opioid use disorder, the draft trial design raises another important question. It proposes that patients stop opioid agonist medications, including buprenorphine and methadone, before receiving ibogaine. Because stopping these treatments can reduce opioid tolerance and create additional risks, the FDA is asking for advice on how researchers should manage this issue safely.
The agency has also clarified the limits of the consultation. It is not seeking public comments on whether ibogaine should be legalized, whether it should be available for religious use, or whether its current Schedule I classification should change.
Separately, ARPA-H is soliciting proposals for early-stage ibogaine research through its ASCENT-IBO program, an initiative not explicitly identified in the FDA’s notice. The deadline for submitting comments to the FDA docket is November 20.
Industry Update: Compass Pathways Discusses Pricing as Its Psilocybin Application Nears Completion
Compass Pathways is moving forward with the development of COMP360, its synthetic psilocybin formulation intended to treat treatment-resistant depression. The company has reported positive results from two Phase 3 clinical trials, COMP005 and COMP006, evaluating the treatment’s effects.
The COMP005 study examined a single 25-milligram dose against a placebo. COMP006, by comparison, evaluated two fixed doses administered three weeks apart. In July, Compass released six-month follow-up data from COMP006 indicating that therapeutic benefits persisted over time.
The company has also been advancing its rolling new drug application (NDA), with final submission anticipated during the fourth quarter of 2026. In April, Compass received permission to use a rolling submission process and was granted a Commissioner’s National Priority Voucher. According to the company, these arrangements could shorten the federal review period to approximately one or two months.
As the regulatory process advances, commercial planning is becoming a more immediate priority. Psychedelic Alpha reported that Compass executives have discussed potential launch pricing and strategies for securing reimbursement from health insurers. Their discussions have included comparisons with Spravato, the esketamine nasal spray developed by Johnson & Johnson and used to treat depression.
Spravato operates under a strict Risk Evaluation and Mitigation Strategy (REMS) program. Its treatment schedule initially requires twice-weekly sessions, followed by ongoing treatments that involve at least two hours of monitoring at a clinic. This structure creates substantial time and facility requirements for patients and healthcare providers.
Compass is positioning COMP360 around a different treatment schedule. The company points to results from COMP006, in which two doses were associated with benefits lasting at least six months. Based on these findings, it argues that some patients might need only a few treatment sessions each year.
That proposed treatment frequency could influence how the company approaches pricing, insurance coverage, and the practical delivery of COMP360 if it reaches the market. However, discussions about commercial positioning do not mean the treatment has been approved or that reimbursement arrangements have been finalized.
Compass expects a potential commercial rollout during the first half of 2027. That timeline depends on two key regulatory steps: FDA approval of COMP360 and subsequent rescheduling by the DEA. Until those requirements are met, the treatment will not become routinely available to patients through a commercial launch.
Psychedelic-Adjacent Policy: State Regulators Say DEA Has Not Answered Rescheduling Questions
State cannabis regulators are raising concerns about limited communication from the DEA following an April 2026 order by Attorney General Todd Blanche. The order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III. Marijuana Moment reported on the regulators’ concerns on October 7.
During a public meeting the previous week, the executive director of the Georgia Access to Medical Cannabis Commission said the DEA had told the commission it could not comment on state labeling proposals intended to align with federal warning requirements.
The chair of Vermont’s Cannabis Control Board described a similar communication problem. According to the chair, a national association representing state regulators had received no meaningful response after sending the agency a list of questions. The main concerns involve DEA registration procedures and product-labeling requirements, both of which could affect how states implement the federal change.
Vermont officials have also identified a need for federal tax guidance. That responsibility, however, falls to tax authorities rather than the DEA. Maryland regulators noted that the April order already exempts state medical marijuana businesses from the federal tax penalty under Section 280E for the 2026 fiscal year.
The uncertainty surrounding implementation comes as two separate federal legal proceedings related to marijuana rescheduling remain unresolved.
On September 29, a DEA administrative law judge paused a separate hearing concerning broader marijuana rescheduling. The government was given until October 13 to respond to opposition motions. Meanwhile, on October 9, the Justice Department and groups challenging the April order, including Smart Approaches to Marijuana, submitted a proposed joint briefing schedule to the U.S. Court of Appeals for the D.C. Circuit.
If the court adopts the proposed schedule, opening briefs would be due November 24, 2026, and final briefs would be expected by February 19, 2027. These proceedings could influence the broader policy debate over marijuana scheduling, but an FDA-approved psychedelic medicine would follow a different legal pathway.
Why DEA Coordination Matters for Future Psychedelic Medicines
Federal law establishes a separate process for scheduling certain drugs after FDA approval. Under 21 U.S.C. § 811(j), the attorney general must issue an interim final scheduling rule within 90 days after a drug is approved and the Department of Health and Human Services recommends placing it in Schedule II through V.
This statutory process differs from the broader marijuana rescheduling litigation. It provides a defined route for changing a drug’s federal classification following the relevant approval and recommendation, although it does not eliminate the practical challenges involved in bringing a new treatment to patients.
Compass Pathways has identified DEA action as a condition of its planned COMP360 launch. The company has also said that states representing approximately 90% of U.S. patients intend to reschedule the treatment within 30 days of federal action.
That expectation depends on effective coordination between federal and state authorities. Yet the complaints from cannabis regulators suggest that communication gaps can complicate the implementation of scheduling changes, including questions about registration, labeling, and related administrative requirements.
The implications extend beyond COMP360. The regulatory path for a psychedelic medicine does not end when the FDA evaluates its safety and effectiveness. Federal scheduling decisions and state-level implementation can also determine when and how an approved treatment becomes accessible in clinical practice.
For now, neither MDMA nor psilocybin has received approval as a medicine, and both remain investigational. Compass’s progress therefore represents a potential future milestone rather than confirmation that psilocybin treatment is already available through an approved commercial product.
Disclosures and Editorial Transparency
Psychedelic State(s) of America (PSA), founded by Jack Gorsline, participates in collaborative initiatives with the Psychedelic Bar Association and maintains active educational and editorial partnerships with Psychedelics Today.
About the Author
Jack Gorsline is an investigative journalist based in Washington, D.C., who covers drug policy reform, with particular attention to psychedelic policy and cannabis legalization advocacy in the United States and internationally.
His work has appeared in the Boston Institute for Nonprofit Journalism (BINJ), Talking Joints Memo, DoubleBlind Magazine, Filter Magazine, Marijuana Moment, Psychedelic Alpha, Lucid News, Cannabis & Tech Today, Reality Sandwich, and High Times Magazine. His reporting has also been featured by Psychedelics Today, Ecstatic Integration, The Mycopreneur Podcast, GBH Radio, and The Microdose from the University of California, Berkeley Center for the Science of Psychedelics, among other outlets.
Gorsline founded both the Psychedelic Writers Guild (PWG) and Psychedelic State(s) of America, a nonprofit-sponsored news organization focused on rigorous, independent psychedelic journalism. Readers can learn more about PSA and support its reporting through the PSA Media Fund link in the organization’s bio. Gorsline is also active on X at @JackGorsline, Instagram at @Jack.Gorseline, LinkedIn, Substack, and Bluesky.
Keeping Tabs
Stay informed about psychedelic news with a regular roundup of developments, educational resources, and upcoming events. Subscribe to receive updates in your inbox every two weeks.
Your information will not be shared, and you can unsubscribe at any time.